|Assessment Status||Assessment process complete|
|Indication||For the treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD).|
|Full pharmacoeconomic assessment commissioned by HSE||12/08/2012|
|NCPE assessment completed||17/08/2012|
|NCPE assessment outcome||Full pharmacoeconomic evaluation not recommended.|
Fluticasone furoate/vilanterol (Relvar™ Ellipta™)
|Assessment Status||Rapid Review Complete|
|Indication||For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.|
|Rapid review commissioned||10/12/2013|
|Rapid review completed||23/12/2013|
|Rapid review outcome||Full Pharmacoeconomic Evaluation not Recommended.|
Meningitis B Vaccine – February 2014
Meningitis B Vaccine – February 2014
Economic Evaluation of a Universal Meningitis B Vaccination Programme in Ireland
In February 2014, the National Centre for Pharmacoeconomics completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document.
New Medicine Horizon Scanning Template
A new medicine horizon scanning template has been developed in consultation with IPHA, HSE, NCCP and the NCPE. It is intended that the document be submitted to each unit, where relevant.
The NCPE hosts pre-submission meetings with Applicants once the Corporate Pharmaceutical Unit has stated that a Health Technology Assessment (HTA) is required to inform a drug reimbursement decision.
What is the purpose of a pre-submission meeting?
The pre-submission meeting provides an opportunity for the Applicant to meet with the NCPE Review Team prior to finalising their HTA submission. The purpose is to outline the proposed approach to the clinical and cost-effectiveness modelling, and to obtain guidance from the NCPE on what may be the most appropriate approaches to adopt. The aim is to help the Applicant provide the best quality HTA submission possible, in order to avoid challenges later in the assessment process.
The NCPE Pre-Submission Meeting Guidance for Applicants contains all of the information to help Applicant’s plan the pre-submission meeting. Please click on the link below to download a copy.
TCD/NCPE Course on Evidence Synthesis
TCD/NCPE Course on Evidence Synthesis – 9th/ 10th September 2013
Trinity College Dublin in collaboration with the NCPE will run a 2 day course on evidence synthesis for health technology assessments (HTAs). The course will provide an introduction to Bayesian analysis using WinBUGs, as applied to evidence synthesis for health economic evaluations. The emphasis will be on practical examples of meta-analyses and mixed treatment comparisons. Code and software to carry out the analyses will be provided. Prior knowledge of WinBUGs will not be necessary. To book a place on this course please contact [email protected]
Course leaders: Professor Cathal Walsh and Dr. Susanne Schmitz
Cost: €500 for two days
R Project Training Course* 1st/2nd July 2013
Teclistamab (Tecvayli®). HTA ID: 22064
|Assessment Status||Awaiting HTA submission from Applicant|
|Indication||As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.|
|Rapid review commissioned||20/09/2022|
|Rapid review completed||03/11/2022|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||29/11/2022|
|Pre-submission consultation with Applicant||24/01/2023|
Update in Pharmacoeconomics 3/4th March 2014
The most recent two day course “Update on Pharmacoeconomics in the Irish Healthcare Setting 2014” took place on the 3rd and 4th March 2014.
Pharmacoeconomics Course Programme 2014
Update in Pharmacoeconomics in the Irish Healthcare Setting March 2015
“An update in Pharmacoeconomics in the Irish Healthcare Setting” 23rd – 24th March 2015.
Course slides now available: http://www.ncpe.ie/education/courses/
Update on Pharmacoeconomics in the Irish Healthcare Setting 2016
the next course an “Update on Pharmacoeconomics in the Irish Healthcare Setting” will take place on 10th and 11th March 2016. This course has been awarded CPD approval to the value of 11 credits.
This course is now full.
Pharmacoeconomics course final 3 2016
A full-time temporary position for a Research Information Specialist.
All relevant information is available from the St James’s Hospital website. Closing date is 19th December 2019.
Enquiries regarding the position can be made to Dr. Lesley Tilson, Chief I Pharmacist (Tel:01 410 3427. Email: [email protected]) or Prof. Michael Barry, Clinical Director (Tel: 01 416 2191. Email: [email protected]).
Statistician (Temporary full time). Closing date 6th June 2022